Dalteparin-Sodium shortage — AU supply status & alternatives

Dalteparin-Sodium

ATC B01AB04

In shortage · Australia

FRAGMIN dalteparin sodium 18

In declared shortage · 🇦🇺 Australia

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Dalteparin-Sodium
Brand names	FRAGMIN dalteparin sodium 18
ATC level 5	B01AB04
ATC level 4	B01AB

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 2 resolved events

◷

0–2 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇦🇺

Australia

TGA · 3h ago

Critical

Verified timeline regulator events

🇦🇺 1 Jan 2027

high reported

🇦🇺 1 June 2026

high reported

🇦🇺 1 Apr 2026

Shortage resolved

🇦🇺 2 Feb 2026

Shortage resolved

🇦🇺 15 July 2025

critical reported

Sources official regulators

🇦🇺

TGA

verified 3h ago

verify ↗

Mederti Drug Report

Generated 1 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.